Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus

Berti, Andrew D.; Harven, Lauren T.; Bingley, Victoria

doi:10.3390/antibiotics9110789

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Telavancin, dalbavancin, and oritavancin belong to the newly developed semisynthetic group of glycopeptides. Hence, the spectrum of antimicrobial activity resembles those of vancomycin and teicoplanin [ 80 , 81 , 82 ]. Their main indications per approval are acute bacterial skin and skin structure infections; in addition, telavancin can be used in pneumonia caused by MRSA as well.…”

Section: Therapy and Prevention—many Old Bugs Little New Drugsmentioning

confidence: 99%

Update on Coagulase-Negative Staphylococci—What the Clinician Should Know

et al. 2021

View full text Add to dashboard Cite

Coagulase-negative staphylococci (CoNS) are among the most frequently recovered bacteria in routine clinical care. Their incidence has steadily increased over the past decades in parallel to the advancement in medicine, especially in regard to the utilization of foreign body devices. Many new species have been described within the past years, while clinical information to most of those species is still sparse. In addition, interspecies differences that render some species more virulent than others have to be taken into account. The distinct populations in which CoNS infections play a prominent role are preterm neonates, patients with implanted medical devices, immunodeficient patients, and those with other relevant comorbidities. Due to the property of CoNS to colonize the human skin, contamination of blood cultures or other samples occurs frequently. Hence, the main diagnostic hurdle is to correctly identify the cases in which CoNS are causative agents rather than contaminants. However, neither phenotypic nor genetic tools have been able to provide a satisfying solution to this problem. Another dilemma of CoNS in clinical practice pertains to their extensive antimicrobial resistance profile, especially in healthcare settings. Therefore, true infections caused by CoNS most often necessitate the use of second-line antimicrobial drugs.

show abstract

Section: Therapy and Prevention—many Old Bugs Little New Drugsmentioning

confidence: 99%

Update on Coagulase-Negative Staphylococci—What the Clinician Should Know

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The rapid development of antibiotic resistance in this patient isolate with an unremarkable mutation rate caused us to suspect a high level of tolerance in the population [ 2 ]. DAP exhibits a pronounced difference in its rate of bacterial killing against tolerant staphylococci making it an ideal antibiotic for their identification [ 15 , 16 ]. Isolate BSN14S1, the six comparators described previously and S .…”

Section: Resultsmentioning

confidence: 99%

Rapid resistance development to three antistaphylococcal therapies in antibiotic-tolerant staphylococcus aureus bacteremia

Miller

Monk²,

Szubin³

et al. 2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Understating how antibiotic tolerance impacts subsequent resistance development in the clinical setting is important to identifying effective therapeutic interventions and prevention measures. This study describes a patient case of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia which rapidly developed resistance to three primary MRSA therapies and identifies genetic and metabolic changes selected in vivo that are associated with rapid resistance evolution. Index blood cultures displayed susceptibility to all (non-beta-lactam) antibiotics with the exception of trimethoprim/ sulfamethoxazole. One month after initial presentation, during the same encounter, blood cultures were again positive for MRSA, now displaying intermediate resistance to vancomycin and ceftaroline and resistance to daptomycin. Two weeks later, blood cultures were positive for a third time, still intermediate resistant to vancomycin and ceftaroline and resistant to daptomycin. Mutations in mprF and vraT were common to all multidrug resistant isolates whereas mutations in tagH, agrB and saeR and secondary mprF mutation emerged sequentially and transiently resulting in distinct in vitro phenotypes. The baseline mutation rate of the patient isolates was unremarkable ruling out the hypermutator phenotype as a contributor to the rapid emergence of resistance. However, the index isolate demonstrated pronounced tolerance to the antibiotic daptomycin, a phenotype that facilitates the subsequent development of resistance during antibiotic exposure. This study exemplifies the capacity of antibiotic-tolerant pathogens to rapidly develop both stable and transient genetic and phenotypic changes, over the course of a single patient encounter.

show abstract

“…Notwithstanding the important (if not essential) value of clinical evaluation, the immediate future for the progression of candidates for MRSA chemotherapy will largely be empirical prioritization. This empirical exploration surely will include further evaluation of β-lactam synergy known additional synergistic pairings identified by in vitro study against multistrain MRSA include ceftaroline-dalbavancin and imipenem-linezolidas well as answers as to whether the lipoglycopeptides (such as dalbavancin and oritavancin) are intrinsically superior to vancomycin ,− or whether fundamentally different approaches to MRSA therapy, such as the use of “metabolism” adjuvants ,− (some as simple as bicarbonate) or lysin (enzymatic) adjuvants. − …”

Section: Against the Fortressmentioning

confidence: 99%

β-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium

Fisher

Mobashery

2020

Chem. Rev.

View full text Add to dashboard Cite

The biological diversity of the unicellular bacteriawhether assessed by shape, food, metabolism, or ecological nichesurely rivals (if not exceeds) that of the multicellular eukaryotes. The relationship between bacteria whose ecological niche is the eukaryote, and the eukaryote, is often symbiosis or stasis. Some bacteria, however, seek advantage in this relationship. One of the most successfulto the disadvantage of the eukaryoteis the small (less than 1 μm diameter) and nearly spherical Staphylococcus aureus bacterium. For decades, successful clinical control of its infection has been accomplished using β-lactam antibiotics such as the penicillins and the cephalosporins. Over these same decades S. aureus has perfected resistance mechanisms against these antibiotics, which are then countered by new generations of β-lactam structure. This review addresses the current breadth of biochemical and microbiological efforts to preserve the future of the β-lactam antibiotics through a better understanding of how S. aureus protects the enzyme targets of the β-lactams, the penicillin-binding proteins. The penicillin-binding proteins are essential enzyme catalysts for the biosynthesis of the cell wall, and understanding how this cell wall is integrated into the protective cell envelope of the bacterium may identify new antibacterials and new adjuvants that preserve the efficacy of the β-lactams.

show abstract

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus

Cited by 4 publications

References 16 publications

Update on Coagulase-Negative Staphylococci—What the Clinician Should Know

Update on Coagulase-Negative Staphylococci—What the Clinician Should Know

Rapid resistance development to three antistaphylococcal therapies in antibiotic-tolerant staphylococcus aureus bacteremia

β-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium

Contact Info

Product

Resources

About